Biodegradable High-efficiency Dengue Vaccine, Method For Making The Same, And Pharmaceutical Composition Comprising The Same

Abstract

The present invention is related to a biodegradable high-efficiency dengue vaccine, a method for making the same, and a pharmaceutical composition comprising the same. The biodegradable high-efficiency dengue vaccine comprises a biodegradable nanocomplex with electric properties holding a dengue viral protein inside. An organism has antibody responses after vaccination with the biodegradable nanocomplex twice. Accordingly, in comparison with the Alum adjuvant and Ribi adjuvant used in the traditional dengue vaccine of the prior art, the vaccination times in the present invention is decreased to further reduce the vaccination cost, so the biodegradable high-efficiency dengue vaccine is good for being a commercial vaccine.

Description

technical field [0001] The present invention relates to a biodegradable high-efficiency dengue vaccine, in particular to a dengue virus protein wrapped in a biodegradable and charged nanocomposite structure, so that it can be recovered after two vaccinations. , that is, the technology that has the expression of antibodies, and at the same time has the ability to greatly increase the production of antibodies, so that the vaccine can more effectively elicit an immune response. Background technique [0002] According to reports, dengue fever, also known as broken bone fever, is an acute viral febrile disease transmitted by Aedes aegypti or Aedes albopictus with fever (39 ℃ to 40℃) or chills, skin rash with aches in extremities, muscle pain, forehead headache, eye socket pain, abdominal pain, back pain (where the bone fever name comes from), sore throat, or possibly vomiting and fainting dizziness and other symptoms; generally referred to as dengue fever refers to the typical d...

AI Technical Summary

Problems solved by technology

[0003] Please refer to "Dengue Vaccine, Pharmaceutical Composition Containing the Dengue Vaccine, and Nucleotide Sequence" disclosed in Taiwan Invention Patent Publication No. 201210614 of the inventor of this application, and "Dengue Vaccine" disclosed in Publication No. 201210615. Dengue vaccine, pharmaceutical composition containing the dengue vaccine, nucleotide sequence, and antibody composition", the above two cases reveal a drug that can remove autoimmunity and reduce cross-reaction with endothelial cells and platelets effect, and shorten the dengue vaccine of bleeding time, these two documents are incorporated herein by reference in full; however, although the above-mentioned dengue vaccine can achieve the expected effect in actual implementation, there are still deficiencies , because the above-mentioned vaccine needs to add the most widely used aluminum hydroxide gel as an adjuvant (also known as an immunostimulant) during actual implementation, and its ability to enhance the immune response in vivo is not very ideal.

Images